Drugs / HRS-8427
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT07073157 | Jul → Aug 2025 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT07049107 | Jun → Jul 2025 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT07049562 | May → Jun 2025 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT07070375 | Apr → Aug 2023 | gram-negative bacterial infections | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06841731 | Apr 2025 → Sep 2026 overdue | bacterial pneumonia | Jiangsu HengRui Medicine Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06144060 | Dec 2023 → Jun 2024 | acute pyelonephritis | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06569056 | Sep 2024 → Sep 2026 | acute pyelonephritis | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HRS-8427 | “HRS-8427 is a novel parenteral siderophore cephalosporin that shows potent efficacy against various gram-negative bacteria, including carbapenem-resistant strains, in vitro and...” PMID 41773934 ↗ Mar 2026 |
| Modality | Small molecule | “HRS-8427 is a novel parenteral siderophore cephalosporin” PMID 41773934 ↗ Mar 2026 |
| Route | Intravenous | “intravenous HRS -8427” NCT06144060 ↗ |